Iradimed (NASDAQ:IRMD - Get Free Report) posted its quarterly earnings results on Monday. The medical equipment provider reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.06), Zacks reports. The company had revenue of $19.51 million during the quarter, compared to the consensus estimate of $19.33 million. Iradimed had a return on equity of 24.12% and a net margin of 26.26%. Iradimed updated its Q2 2025 guidance to 0.410-0.440 EPS and its FY 2025 guidance to 1.710-1.810 EPS.
Iradimed Stock Down 1.7 %
IRMD traded down $0.88 during trading on Friday, hitting $51.79. The company had a trading volume of 24,445 shares, compared to its average volume of 43,511. The company has a market capitalization of $658.51 million, a PE ratio of 34.53 and a beta of 0.91. The firm's 50-day moving average price is $52.10 and its 200 day moving average price is $54.34. Iradimed has a one year low of $41.60 and a one year high of $63.29.
Iradimed Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, May 30th. Investors of record on Tuesday, May 20th will be paid a dividend of $0.17 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $0.68 dividend on an annualized basis and a yield of 1.31%. Iradimed's payout ratio is 43.87%.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on the company. Roth Mkm reaffirmed a "buy" rating and issued a $72.00 price target (up from $60.00) on shares of Iradimed in a research note on Friday, February 14th. StockNews.com upgraded shares of Iradimed from a "buy" rating to a "strong-buy" rating in a report on Tuesday.
Get Our Latest Research Report on Iradimed
Iradimed Company Profile
(
Get Free Report)
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Further Reading

Before you consider Iradimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Iradimed wasn't on the list.
While Iradimed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.